Ligand Buys Royalty Rights In Santen's Ryjunea Eye Drug
(RTTNews) - Ligand Pharmaceuticals Inc. (LGND), announced on Tuesday that it has acquired royalty and milestone payment rights tied to Santen Pharmaceutical Co. Ltd's Ryjunea, the first approved pharmacologic treatment in Europe and the UK to slow myopia progression in children.